Pfizer to end license deal with Syros for blood disorder therapies
(Reuters) - Syros Pharmaceuticals said on Friday Pfizer will terminate a license deal between the companies related to the development of novel therap...
Stay updated with breaking news from Friday Pfizer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(Reuters) - Syros Pharmaceuticals said on Friday Pfizer will terminate a license deal between the companies related to the development of novel therap...
Shares of Syros were down 5.7% in trading after the bell. The termination will end the company's more than three-year long collaboration with sickle cell disease drugmaker Global Blood Therapeutics (GBT) that Pfizer bought in a $5.4 billion deal last August.
Syros Pharmaceuticals said on Friday Pfizer will terminate a license deal between the companies related to the development of novel therapies for two blood disorders. Shares of Syros...
At a stroke, the pharmaceutical company has become nearly $7 billion larger with a new asset.